Literature DB >> 19147382

Potential choline kinase inhibitors: a molecular modeling study of bis-quinolinium compounds.

P Srivani1, G Narahari Sastry.   

Abstract

Choline kinase (ChoK) is reported to involve in cell signaling pathways and cell growth by regulating the intermediate, phosphocholine (PCho), which is the first step to biosynthesis a membrane phospholipid, phosphatidylcholine. The PCho levels are overexpressed due to elevated activation of the protein under carcinogenesis conditions. ChoK has thus evolved as a novel target for various cancers and a range of compounds has been reported in this course as potent ChoK inhibitors. However, not much information is known about the binding site of the inhibitors. Therefore, we ventured to unravel the possible binding site of 39 bis-quinolinium inhibitors from which the structural requirement for better protein-ligand complex was delved. Molecular docking and 3D-QSAR studies namely comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) were performed on the series. The knowledge of the active site was obtained from the site id search and molcad surface calculations of Sybyl, which was further considered for docking studies. In 3D-QSAR, the best predictions were obtained from the model where 29 compounds were considered in the training set and remaining 10 in the test set. The best CoMFA statistics were obtained with r(2) of 0.99 and q(2) of 0.81 while, CoMSIA was resulted with r(2) of 0.98 and q(2) of 0.77. A comparative analysis was done with the resulted 3D-QSAR maps and the docked poses by overlaying the maps on the active site residues. Since, there is no reported ligand co-crystallized structure of ChoK the present study provides valuable clues on the binding conformation of the ligand and its interactions with the active site.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19147382     DOI: 10.1016/j.jmgm.2008.10.010

Source DB:  PubMed          Journal:  J Mol Graph Model        ISSN: 1093-3263            Impact factor:   2.518


  6 in total

1.  Analogue-based approaches in anti-cancer compound modelling: the relevance of QSAR models.

Authors:  Mohammed Hussaini Bohari; Hemant Kumar Srivastava; Garikapati Narahari Sastry
Journal:  Org Med Chem Lett       Date:  2011-07-18

2.  FDA approved drugs complexed to their targets: evaluating pose prediction accuracy of docking protocols.

Authors:  Mohammed H Bohari; G Narahari Sastry
Journal:  J Mol Model       Date:  2012-05-08       Impact factor: 1.810

3.  Design of 1-arylsulfamido-2-alkylpiperazine derivatives as secreted PLA2 inhibitors.

Authors:  Preethi Badrinarayan; P Srivani; G Narahari Sastry
Journal:  J Mol Model       Date:  2010-06-23       Impact factor: 1.810

4.  4-aminoquinolines active against chloroquine-resistant Plasmodium falciparum: basis of antiparasite activity and quantitative structure-activity relationship analyses.

Authors:  Simon J Hocart; Huayin Liu; Haiyan Deng; Dibyendu De; Frances M Krogstad; Donald J Krogstad
Journal:  Antimicrob Agents Chemother       Date:  2011-03-07       Impact factor: 5.191

5.  Crystal structures of human choline kinase isoforms in complex with hemicholinium-3: single amino acid near the active site influences inhibitor sensitivity.

Authors:  Bum Soo Hong; Abdellah Allali-Hassani; Wolfram Tempel; Patrick J Finerty; Farrell Mackenzie; Svetoslav Dimov; Masoud Vedadi; Hee-Won Park
Journal:  J Biol Chem       Date:  2010-03-18       Impact factor: 5.157

6.  Combined 5-FU and ChoKα inhibitors as a new alternative therapy of colorectal cancer: evidence in human tumor-derived cell lines and mouse xenografts.

Authors:  Ana de la Cueva; Ana Ramírez de Molina; Néstor Alvarez-Ayerza; Ma Angeles Ramos; Arancha Cebrián; Teresa Gómez Del Pulgar; Juan Carlos Lacal
Journal:  PLoS One       Date:  2013-06-10       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.